German science and technology company Merck on Thursday forecast its net sales to be in the range of
21.5 billion ($23.2 billion) and
22.9 billion in 2025. It also projects its adjusted earnings before interest,
Merck & Co. Inc. has forecasted a slight increase in both earnings and sales for the year 2025, as reported in their recent financial outlook. The pharmaceutical giant expects this growth to be driven by its diverse portfolio, including strong performances from its oncology and vaccine divisions. Despite facing challenges such as patent expirations and competition from generics, Merck anticipates that new product launches and strategic acquisitions will bolster its revenue. The company also highlighted ongoing investments in research and development, aiming to innovate and expand its product offerings. This outlook reflects Merck's confidence in navigating the complex pharmaceutical market dynamics while continuing to deliver value to its shareholders.